Julie Christine Lauffenburger, Ph.D., Pharm.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Medication Adherence | 32 | 2024 | 2176 | 4.560 |
Why?
|
Prescription Drugs | 5 | 2023 | 631 | 1.680 |
Why?
|
Inappropriate Prescribing | 4 | 2024 | 211 | 1.660 |
Why?
|
Pharmaceutical Services | 6 | 2021 | 141 | 1.530 |
Why?
|
Pharmacy | 2 | 2022 | 91 | 1.410 |
Why?
|
Hypoglycemic Agents | 10 | 2024 | 3081 | 1.350 |
Why?
|
Hypertension | 16 | 2024 | 8542 | 1.330 |
Why?
|
Insurance, Pharmaceutical Services | 4 | 2023 | 348 | 1.300 |
Why?
|
Chronic Disease | 11 | 2021 | 9320 | 1.070 |
Why?
|
Diabetes Mellitus, Type 2 | 9 | 2023 | 12143 | 0.890 |
Why?
|
Health Expenditures | 6 | 2023 | 2366 | 0.880 |
Why?
|
Antidepressive Agents, Tricyclic | 1 | 2024 | 432 | 0.790 |
Why?
|
Electronic Prescribing | 1 | 2021 | 114 | 0.710 |
Why?
|
Touch Perception | 1 | 2021 | 107 | 0.710 |
Why?
|
Antihypertensive Agents | 8 | 2024 | 2023 | 0.690 |
Why?
|
Pharmacies | 2 | 2021 | 169 | 0.680 |
Why?
|
Pharmacists | 4 | 2019 | 260 | 0.680 |
Why?
|
Reinforcement, Social | 1 | 2018 | 10 | 0.650 |
Why?
|
Anticoagulants | 6 | 2024 | 4813 | 0.630 |
Why?
|
Gout | 2 | 2023 | 621 | 0.620 |
Why?
|
Cardiovascular Agents | 3 | 2019 | 840 | 0.610 |
Why?
|
Medicare | 12 | 2024 | 6770 | 0.600 |
Why?
|
Nurse Practitioners | 1 | 2021 | 271 | 0.590 |
Why?
|
Glycemic Index | 1 | 2020 | 396 | 0.570 |
Why?
|
Patient-Centered Care | 2 | 2017 | 1422 | 0.550 |
Why?
|
Uric Acid | 1 | 2023 | 807 | 0.540 |
Why?
|
Warfarin | 3 | 2024 | 1483 | 0.540 |
Why?
|
Cardiovascular Diseases | 7 | 2023 | 15498 | 0.530 |
Why?
|
Insulin | 3 | 2020 | 6602 | 0.530 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2023 | 3244 | 0.520 |
Why?
|
Drug Prescriptions | 3 | 2024 | 1669 | 0.520 |
Why?
|
Metformin | 1 | 2023 | 906 | 0.510 |
Why?
|
Complementary Therapies | 1 | 2020 | 486 | 0.510 |
Why?
|
United States | 32 | 2024 | 72339 | 0.510 |
Why?
|
Health Care Costs | 2 | 2020 | 3243 | 0.500 |
Why?
|
Fee-for-Service Plans | 1 | 2020 | 700 | 0.500 |
Why?
|
Medical Informatics | 1 | 2022 | 732 | 0.500 |
Why?
|
Medication Therapy Management | 2 | 2017 | 130 | 0.500 |
Why?
|
Community Pharmacy Services | 2 | 2012 | 52 | 0.490 |
Why?
|
Atrial Fibrillation | 5 | 2024 | 5127 | 0.490 |
Why?
|
Retrospective Studies | 28 | 2024 | 80582 | 0.490 |
Why?
|
Vaccines | 1 | 2023 | 837 | 0.480 |
Why?
|
Communication | 4 | 2022 | 3871 | 0.470 |
Why?
|
Cost Control | 1 | 2017 | 628 | 0.460 |
Why?
|
Health Services Needs and Demand | 1 | 2022 | 1403 | 0.460 |
Why?
|
Humans | 82 | 2024 | 761423 | 0.460 |
Why?
|
Shock, Septic | 1 | 2020 | 768 | 0.460 |
Why?
|
Diabetes Complications | 1 | 2020 | 1315 | 0.440 |
Why?
|
Medicare Part D | 2 | 2019 | 355 | 0.430 |
Why?
|
Female | 54 | 2024 | 392581 | 0.430 |
Why?
|
Primary Health Care | 6 | 2024 | 4686 | 0.410 |
Why?
|
Polypharmacy | 3 | 2021 | 305 | 0.400 |
Why?
|
Social Support | 1 | 2022 | 2172 | 0.400 |
Why?
|
Male | 46 | 2024 | 360736 | 0.390 |
Why?
|
Antidepressive Agents | 1 | 2024 | 2897 | 0.390 |
Why?
|
Aged | 34 | 2024 | 169235 | 0.390 |
Why?
|
Adrenal Cortex Hormones | 1 | 2020 | 1876 | 0.390 |
Why?
|
Analgesics, Opioid | 3 | 2023 | 3804 | 0.380 |
Why?
|
Diabetes Mellitus | 7 | 2021 | 5840 | 0.380 |
Why?
|
Life Change Events | 1 | 2016 | 952 | 0.370 |
Why?
|
Middle Aged | 33 | 2024 | 220826 | 0.370 |
Why?
|
Formularies as Topic | 1 | 2011 | 94 | 0.360 |
Why?
|
Databases, Factual | 4 | 2016 | 7956 | 0.360 |
Why?
|
Electronic Health Records | 4 | 2024 | 4811 | 0.340 |
Why?
|
Prescriptions | 2 | 2023 | 386 | 0.340 |
Why?
|
Self Report | 4 | 2023 | 3724 | 0.340 |
Why?
|
Hyperlipidemias | 4 | 2018 | 771 | 0.340 |
Why?
|
Pharmacoepidemiology | 1 | 2013 | 350 | 0.330 |
Why?
|
Patient Participation | 2 | 2024 | 1444 | 0.330 |
Why?
|
Patient Compliance | 1 | 2019 | 2690 | 0.310 |
Why?
|
Drugs, Generic | 1 | 2013 | 448 | 0.300 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2015 | 1116 | 0.300 |
Why?
|
Family | 1 | 2018 | 3197 | 0.290 |
Why?
|
Telephone | 2 | 2022 | 627 | 0.290 |
Why?
|
Heart Failure | 4 | 2024 | 11674 | 0.280 |
Why?
|
Sepsis | 1 | 2020 | 2585 | 0.270 |
Why?
|
Health Behavior | 1 | 2018 | 2641 | 0.270 |
Why?
|
Hepatitis C, Chronic | 1 | 2014 | 1032 | 0.260 |
Why?
|
Telemedicine | 2 | 2021 | 3051 | 0.260 |
Why?
|
Decision Making | 2 | 2022 | 3929 | 0.260 |
Why?
|
Insurance Claim Review | 3 | 2020 | 741 | 0.260 |
Why?
|
Thrombolytic Therapy | 1 | 2015 | 2065 | 0.260 |
Why?
|
Internship and Residency | 2 | 2024 | 5879 | 0.250 |
Why?
|
Drug Costs | 2 | 2023 | 1183 | 0.250 |
Why?
|
Blood Pressure | 6 | 2023 | 8487 | 0.240 |
Why?
|
Long-Term Care | 2 | 2020 | 633 | 0.240 |
Why?
|
Adult | 24 | 2024 | 221148 | 0.230 |
Why?
|
Insurance, Health | 1 | 2017 | 2497 | 0.230 |
Why?
|
Physicians | 1 | 2022 | 4591 | 0.230 |
Why?
|
Cholinergic Antagonists | 1 | 2024 | 168 | 0.210 |
Why?
|
Atherosclerosis | 3 | 2023 | 3407 | 0.200 |
Why?
|
Cohort Studies | 9 | 2023 | 41446 | 0.200 |
Why?
|
Administration, Oral | 4 | 2024 | 4016 | 0.200 |
Why?
|
Antiviral Agents | 1 | 2014 | 3057 | 0.200 |
Why?
|
Aged, 80 and over | 11 | 2024 | 58956 | 0.200 |
Why?
|
Risk Assessment | 5 | 2024 | 23990 | 0.190 |
Why?
|
Blood Pressure Determination | 2 | 2022 | 634 | 0.190 |
Why?
|
Brain Ischemia | 1 | 2015 | 3049 | 0.190 |
Why?
|
Patient Care | 2 | 2020 | 621 | 0.190 |
Why?
|
Qualitative Research | 2 | 2022 | 3023 | 0.190 |
Why?
|
Gout Suppressants | 1 | 2023 | 177 | 0.190 |
Why?
|
Tranexamic Acid | 1 | 2023 | 176 | 0.190 |
Why?
|
Antifibrinolytic Agents | 1 | 2023 | 292 | 0.180 |
Why?
|
Blood Glucose | 3 | 2020 | 6391 | 0.170 |
Why?
|
Electronics | 1 | 2021 | 317 | 0.170 |
Why?
|
Medical Staff, Hospital | 1 | 2024 | 601 | 0.170 |
Why?
|
Insurance Carriers | 1 | 2021 | 156 | 0.170 |
Why?
|
Logistic Models | 4 | 2019 | 13255 | 0.170 |
Why?
|
New Jersey | 1 | 2020 | 295 | 0.170 |
Why?
|
Behavior Control | 1 | 2019 | 47 | 0.160 |
Why?
|
Vaccination | 2 | 2023 | 3381 | 0.160 |
Why?
|
Myocardial Infarction | 3 | 2015 | 11458 | 0.160 |
Why?
|
Technology | 1 | 2021 | 292 | 0.160 |
Why?
|
Postal Service | 1 | 2018 | 96 | 0.150 |
Why?
|
Drugs, Investigational | 2 | 2018 | 212 | 0.150 |
Why?
|
Benzodiazepines | 1 | 2024 | 1132 | 0.150 |
Why?
|
Medicare Part B | 1 | 2019 | 117 | 0.150 |
Why?
|
Public Health | 1 | 2011 | 2666 | 0.150 |
Why?
|
Secondary Prevention | 1 | 2024 | 1474 | 0.150 |
Why?
|
Remote Consultation | 1 | 2020 | 237 | 0.150 |
Why?
|
Frail Elderly | 1 | 2023 | 763 | 0.150 |
Why?
|
Policy | 1 | 2021 | 508 | 0.140 |
Why?
|
Adenosine Diphosphate | 1 | 2018 | 422 | 0.140 |
Why?
|
Risk Factors | 9 | 2023 | 74167 | 0.140 |
Why?
|
Hypnotics and Sedatives | 1 | 2024 | 1179 | 0.130 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2022 | 1039 | 0.130 |
Why?
|
Minority Groups | 1 | 2023 | 1203 | 0.130 |
Why?
|
Cost Sharing | 1 | 2019 | 409 | 0.120 |
Why?
|
Reminder Systems | 1 | 2018 | 388 | 0.120 |
Why?
|
Biotransformation | 1 | 2014 | 166 | 0.120 |
Why?
|
Cross-Sectional Studies | 3 | 2024 | 26112 | 0.120 |
Why?
|
Comorbidity | 3 | 2020 | 10498 | 0.120 |
Why?
|
Cytochrome P-450 CYP3A | 1 | 2014 | 114 | 0.120 |
Why?
|
Small-Area Analysis | 1 | 2014 | 55 | 0.120 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2021 | 10203 | 0.120 |
Why?
|
Follow-Up Studies | 4 | 2020 | 39117 | 0.110 |
Why?
|
Drug Approval | 2 | 2018 | 814 | 0.110 |
Why?
|
Drug Utilization Review | 1 | 2014 | 248 | 0.110 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2016 | 857 | 0.100 |
Why?
|
Prevalence | 3 | 2021 | 15717 | 0.100 |
Why?
|
Education, Pharmacy | 1 | 2012 | 38 | 0.100 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 2 | 2022 | 1517 | 0.100 |
Why?
|
Referral and Consultation | 2 | 2022 | 3600 | 0.100 |
Why?
|
Patient Care Planning | 1 | 2017 | 908 | 0.100 |
Why?
|
Income | 1 | 2020 | 1876 | 0.100 |
Why?
|
Odds Ratio | 1 | 2024 | 9645 | 0.100 |
Why?
|
International Normalized Ratio | 1 | 2013 | 382 | 0.090 |
Why?
|
Platelet Aggregation Inhibitors | 2 | 2024 | 2751 | 0.090 |
Why?
|
Adaptation, Psychological | 1 | 2021 | 2632 | 0.090 |
Why?
|
Regression Analysis | 2 | 2018 | 6343 | 0.090 |
Why?
|
Treatment Failure | 1 | 2016 | 2642 | 0.090 |
Why?
|
Propensity Score | 2 | 2015 | 1908 | 0.090 |
Why?
|
Cross-Over Studies | 1 | 2016 | 2076 | 0.090 |
Why?
|
Malawi | 1 | 2011 | 304 | 0.090 |
Why?
|
Drug Interactions | 1 | 2014 | 1414 | 0.090 |
Why?
|
Health Status Disparities | 1 | 2021 | 1852 | 0.080 |
Why?
|
Research Design | 3 | 2021 | 6178 | 0.080 |
Why?
|
Publishing | 1 | 2016 | 833 | 0.080 |
Why?
|
Socioeconomic Factors | 2 | 2020 | 7825 | 0.080 |
Why?
|
Sex Distribution | 1 | 2013 | 2281 | 0.080 |
Why?
|
Cesarean Section | 1 | 2017 | 1396 | 0.080 |
Why?
|
Comparative Effectiveness Research | 1 | 2013 | 709 | 0.080 |
Why?
|
Public Policy | 1 | 2012 | 559 | 0.080 |
Why?
|
Survival Analysis | 1 | 2020 | 10089 | 0.070 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2013 | 1241 | 0.070 |
Why?
|
Registries | 1 | 2024 | 8223 | 0.070 |
Why?
|
Age Distribution | 1 | 2013 | 2880 | 0.070 |
Why?
|
Drug Utilization | 1 | 2013 | 1188 | 0.070 |
Why?
|
Cost-Benefit Analysis | 1 | 2020 | 5492 | 0.070 |
Why?
|
Influenza, Human | 1 | 2018 | 1521 | 0.070 |
Why?
|
Intensive Care Units | 1 | 2020 | 3744 | 0.070 |
Why?
|
Prognosis | 2 | 2020 | 29620 | 0.070 |
Why?
|
Treatment Outcome | 4 | 2024 | 64651 | 0.070 |
Why?
|
Decision Support Techniques | 1 | 2017 | 1998 | 0.070 |
Why?
|
Health Personnel | 1 | 2021 | 3335 | 0.070 |
Why?
|
Hypolipidemic Agents | 2 | 2024 | 609 | 0.070 |
Why?
|
Drug Monitoring | 1 | 2013 | 962 | 0.070 |
Why?
|
Chi-Square Distribution | 1 | 2013 | 3418 | 0.070 |
Why?
|
Pain, Postoperative | 1 | 2017 | 1737 | 0.070 |
Why?
|
Drug Therapy, Combination | 1 | 2017 | 6309 | 0.070 |
Why?
|
Intention to Treat Analysis | 2 | 2018 | 413 | 0.070 |
Why?
|
Young Adult | 4 | 2021 | 59207 | 0.070 |
Why?
|
Bone Density Conservation Agents | 1 | 2013 | 795 | 0.070 |
Why?
|
Delivery of Health Care | 2 | 2022 | 5335 | 0.070 |
Why?
|
Reimbursement Mechanisms | 1 | 2012 | 667 | 0.070 |
Why?
|
Focus Groups | 1 | 2012 | 1413 | 0.070 |
Why?
|
Sensitivity and Specificity | 1 | 2020 | 14664 | 0.060 |
Why?
|
Evidence-Based Medicine | 2 | 2014 | 3687 | 0.060 |
Why?
|
Combined Modality Therapy | 1 | 2017 | 8529 | 0.060 |
Why?
|
Adolescent | 4 | 2021 | 88313 | 0.060 |
Why?
|
Opioid-Related Disorders | 1 | 2019 | 2162 | 0.060 |
Why?
|
Sex Factors | 2 | 2015 | 10548 | 0.060 |
Why?
|
Transcription Factors | 1 | 2024 | 12125 | 0.060 |
Why?
|
Hospitalization | 1 | 2024 | 10718 | 0.060 |
Why?
|
Osteoporosis | 1 | 2013 | 1605 | 0.060 |
Why?
|
Residence Characteristics | 1 | 2014 | 2092 | 0.060 |
Why?
|
Disease Progression | 1 | 2020 | 13502 | 0.050 |
Why?
|
Linear Models | 1 | 2013 | 5869 | 0.050 |
Why?
|
Hemoptysis | 1 | 2023 | 152 | 0.050 |
Why?
|
Denmark | 1 | 2024 | 771 | 0.050 |
Why?
|
Digoxin | 1 | 2022 | 246 | 0.050 |
Why?
|
Time Factors | 2 | 2024 | 39975 | 0.050 |
Why?
|
Habits | 1 | 2021 | 147 | 0.050 |
Why?
|
Ambulatory Care | 1 | 2012 | 2775 | 0.050 |
Why?
|
Administration, Inhalation | 1 | 2023 | 1156 | 0.040 |
Why?
|
Longitudinal Studies | 1 | 2017 | 14599 | 0.040 |
Why?
|
Glucagon-Like Peptide 1 | 1 | 2023 | 364 | 0.040 |
Why?
|
Age Factors | 3 | 2024 | 18400 | 0.040 |
Why?
|
Pyridones | 1 | 2024 | 809 | 0.040 |
Why?
|
Behavioral Sciences | 1 | 2018 | 29 | 0.040 |
Why?
|
Stroke | 2 | 2024 | 9756 | 0.040 |
Why?
|
Biphenyl Compounds | 1 | 2022 | 1007 | 0.040 |
Why?
|
Thiazoles | 1 | 2024 | 1517 | 0.040 |
Why?
|
Early Termination of Clinical Trials | 1 | 2016 | 69 | 0.030 |
Why?
|
Quality of Health Care | 1 | 2012 | 4330 | 0.030 |
Why?
|
Patient Acceptance of Health Care | 2 | 2022 | 3204 | 0.030 |
Why?
|
Tetrazoles | 1 | 2022 | 909 | 0.030 |
Why?
|
Deductibles and Coinsurance | 1 | 2018 | 316 | 0.030 |
Why?
|
Drug Combinations | 1 | 2022 | 2048 | 0.030 |
Why?
|
Immunization Programs | 1 | 2018 | 268 | 0.030 |
Why?
|
Antineoplastic Agents | 1 | 2018 | 13637 | 0.030 |
Why?
|
Evidence-Based Practice | 1 | 2018 | 495 | 0.030 |
Why?
|
Pyrazoles | 1 | 2024 | 2007 | 0.030 |
Why?
|
Students, Pharmacy | 1 | 2012 | 17 | 0.030 |
Why?
|
Pyridines | 1 | 2024 | 2875 | 0.030 |
Why?
|
Safety | 1 | 2016 | 1150 | 0.020 |
Why?
|
Injections | 1 | 2013 | 830 | 0.020 |
Why?
|
Obstetrics | 1 | 2017 | 665 | 0.020 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2024 | 4014 | 0.020 |
Why?
|
Professional Role | 1 | 2012 | 314 | 0.020 |
Why?
|
United States Food and Drug Administration | 1 | 2018 | 1664 | 0.020 |
Why?
|
Social Class | 1 | 2018 | 2004 | 0.020 |
Why?
|
Faculty | 1 | 2012 | 383 | 0.020 |
Why?
|
Neoplasms | 1 | 2018 | 22164 | 0.020 |
Why?
|
Healthcare Disparities | 1 | 2024 | 3357 | 0.020 |
Why?
|
Stroke Volume | 1 | 2022 | 5497 | 0.020 |
Why?
|
Advisory Committees | 1 | 2012 | 786 | 0.020 |
Why?
|
Patient Selection | 1 | 2019 | 4244 | 0.020 |
Why?
|
Risk | 1 | 2018 | 9612 | 0.020 |
Why?
|
Medicaid | 1 | 2019 | 2818 | 0.020 |
Why?
|
Periodicals as Topic | 1 | 2016 | 1463 | 0.020 |
Why?
|
Teaching | 1 | 2012 | 1169 | 0.010 |
Why?
|
Exercise | 1 | 2019 | 5884 | 0.010 |
Why?
|
Prospective Studies | 2 | 2018 | 54415 | 0.010 |
Why?
|
Pregnancy | 1 | 2017 | 29862 | 0.010 |
Why?
|